Chronic Kidney Disease Market Research Report - Forecast to 2030

Chronic Kidney Disease Market Research Report Information by Diagnosis (Blood Test, Urine Test, Imaging Test, and Kidney Biopsy), by Treatment (Drugs, Dialysis, and Kidney Transplant) , by Indication (Type 1 Or Type 2 Diabetes, High Blood Pressure, and Polycystic Kidney Disease), by End User (Hospital & Clinics and Diagnostic Centers), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030

ID: MRFR/Pharma/4289-HCR | 110 Pages | Author: Rahul Gotadki | March 2024         

Chronic Kidney Disease Market Speak to Analyst Request a Free Sample

Global Chronic Kidney Disease Market Overview


The chronic kidney disease market size was valued at USD 65.88 billion in 2022. The chronic kidney disease market industry is projected to grow from USD 69.44 Billion in 2023 to USD 101.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5% during the forecast period (2023 - 2030).The increasing prevalence of kidney diseases, the increasing number of biopsy procedures, and the rising demand for new techniques for diagnosis of chronic diseases are driving the market growth.


Global Chronic Kidney Disease Market Overview


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


kidney illness, and the rising number of biopsy operations are all factors fueling the market. Increases in governmental spending and the development of more sensitive diagnostic tools for identifying CKD at an early stage are further factors that should drive the market forward.


The chronic kidney disease (CKD) market is expected to increase because of factors such as the increasing popularity of transplantation therapy and the presence of a sizable elderly population. The high level of R&D activity in the expansion of CKD medications and the favorable reimbursement policies in emerging nations are also expected to drive the market growth rate. Market growth for chronic kidney disease (CKD) is also predicted to be influenced by the focus of various manufacturers on innovation and technological breakthroughs in treatment.


The prevalence of CKD is high and rising in many regions of the world, which is expected to boost demand for blood testing. End-stage renal disease (ESRD) is extremely common and rapidly increasing in prevalence around the world. As a result, it opens up new avenues for business expansion.

In July, 2023, Recent work by a team at the University of Edinburgh sheds light on a protein associated to kidney and heart damage, which may lead to new approaches to treating chronic kidney disease. Researchers have found that the protein Indian Hedgehog (IHH) promotes scarring in the kidneys and hearts of mice. Damaged or aging kidneys manufacture and release this protein from certain cells. Chronic kidney disease (CKD) affects 10% of the global population, and experts say further research is needed to investigate IHH as a possible target for medicines to treat CKD.


Chronic Kidney Disease Market Trends



  • The  increasing prevalence of kidney diseases to boost the market growth


The worldwide rise in the prevalence and incidence of obesity is the main factor driving the growth of the chronic kidney disease device market. For instance, the World Health Organization estimated that over 1 billion people worldwide 650 million adults, 340 million adolescents, and 39 million children are obese as of March 2022. Additionally, by 2025, 167 million people and children who are overweight or obese will also have worse health overall. As a result of the rising obesity rate, more people are anticipated to seek out chronic kidney disease during the forecast period.


Furthermore, Additionally, according to data from the American Cancer Society for 2022, there are projected to be about 79,000 new cases of kidney cancer in the country that year (50,290 men and 28,710 women). The lifetime chance of developing kidney cancer is higher in males (2.02%) than in women (1.03%), according to the same source. This is expected to spur market expansion over the coming years.


Chronic Kidney Disease Market Segment Insights


Chronic Kidney Disease Diagnosis Insights


The chronic kidney disease market segmentation, based on diagnosis, includes blood test, urine test, imaging test, and kidney biopsy. The blood tests segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to rising burden of chronic kidney disease and expanding technologically advanced diagnostic products. In addition, the major test for the diagnosis of renal disease combines a blood test and aids in determining how well the kidneys are functioning. The blood test measures blood amounts of a secondary effect known as creatinine.


May 2021:FDA approved Farxiga by AstraZeneca for treating chronic kidney disease (CKD) in people with and without type-2 diabetes who are at risk of progression.


Figure 2: CHRONIC KIDNEY DISEASE MARKET, BY DIAGNOSIS, 2022 & 2030 (USD BILLION)


CHRONIC KIDNEY DISEASE MARKET, BY DIAGNOSIS, 2022 & 2030


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Chronic Kidney Disease Treatment Insights


The chronic kidney disease market segmentation, based on Treatment, includes drugs, dialysis, and kidney transplant. The drugs segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to increased government support for research and development, and the availability of funding for research contributions. Furthermore, A growing focus on the development of new drugs increased government support for research and development, and the availability of funding for research contributions.


Chronic Kidney Disease Indication Insights


The chronic kidney disease market segmentation, based on indication, includes Type 1 Or type 2 diabetes, high blood pressure, and polycystic kidney disease. The Type 1 or type 2 diabetes segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to rising prevalence of diabetes, rising prevalence of obesity, changing lifestyles, and new product approvals, as well as those factors, as well as rising prevalence of diabetes, rising prevalence of obesity, and changing lifestyle. In addition, according to the CDC, in 2018, 34.2 million people in the US, or 10.5% of the US population, had diabetes. Of these 34.2 million adults with diabetes, 26.8 million were diagnosed with diabetes, while 7.3 million people were still undiagnosed. Also, the proportion of undiagnosed diabetes was 30%-40% in Europe in 2019.


Chronic Kidney Disease End User Insights


The chronic kidney disease market segmentation is based on end-user that includes hospital & clinics and diagnostic centers. The hospital & clinics segment has dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the availability of advanced technological devices and the increase in diabetes and chronic kidney disease decreases, the increasing number weekly dialysis in the hospitals and clinics, together with the development of wellness trends, particularly in developed countries.

In July, 2023,The National Institutes of Health (NIH) funded a collaborative project between the University of California (UC) San Diego, Washington University, and other institutions to develop an atlas tool to facilitate treatment for kidney illness by study of cells and nuclei. It can be challenging to evaluate and investigate treatments for renal problems due to the complexity of the kidney organ. However, a fresh method has been taken in the Kidney Tissue Atlas. KPMP's goal is to improve treatment for chronic kidney disease and acute kidney injury (AKI) by investigating the strong possibility that both conditions have distinct origins. Educating yourself on the various illness mechanisms and their causes will help you treat the condition more effectively.

Jardiance (empagliflozin), manufactured by Eli Lilly and Boehringer Ingelheim, was authorized by the European Commission (EC) on July 20, 2023, for the treatment of adults with chronic kidney disease (CKD). Patients with type 2 diabetes and cardiovascular disease are the first to have mortality reduction data included in the label for the oral, once-daily, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. Over 47 million people in the EU suffer from CKD, and the approval of empagliflozin by the EC has the potential to improve their quality of life. Patients with CKD will have a lower chance of being hospitalized for any reason.


Chronic Kidney Disease Regional Insights


By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America chronic kidney disease market is expected to be the fastest growing during the study period. This is attributed to the rising prevalence of chronic kidney diseases, the presence of well-established healthcare infrastructure along with high health spending, and technologically advanced diagnostic tests in the region. Moreover, the primary reason fueling the market's expansion is the rising prevalence of chronic kidney diseases in the population. For instance, according to a study released in February 2022 by the American Kidney Fund, 92,000 Americans are waiting for kidney transplants and an estimated 37 million Americans have kidney disease. Therefore, the rising rates of chronic renal disease, a developed healthcare system, high health spending, and technologically sophisticated diagnostic procedures are the main drivers of market expansion.


Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: CHRONIC KIDNEY DISEASE MARKET SHARE BY REGION, 2022 & 2030 (USD BILLION)


CHRONIC KIDNEY DISEASE MARKET SHARE BY REGION, 2022 & 2030


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Europe chronic kidney disease market is expected to account for the second-largest market share due to the increasing incidences of chronic kidney diseases and growth in government expenditure in the healthcare sector in the region. Further, the Germany chronic kidney disease market is expected to hold 3rd place for the market share, and the UK chronic kidney disease market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France chronic kidney disease market will hold the 5th place for the market share.


The Asia-Pacific chronic kidney disease market is expected to grow at a CAGR of XX% from 2022 to 2030. This is due to the due to the increasing incidences of end-stage diseases and high development in government expenditure in the healthcare industry in the Asia-Pacific region. Moreover, India chronic kidney disease market is expected to hold the largest market share, and China chronic kidney disease market is expected fastest-growing market in the Asia-Pacific region.


Furthermore, India is considered as one of the countries with the highest growth rates in the healthcare sector. Due to an increase in life expectancy and illnesses brought on by a sedentary lifestyle is considerably increasing which will fuel the growth for the chronic kidney disease market.


The Rest of the World includes the Middle East, Africa, and Latin America. This segment is projected to hold the least share in the chronic kidney disease market. In this region, the Middle East is anticipated to dominate owing to the as rising prevalence of diabetes resulting in renal diseases and rising incidences of renal diseases in the region. Furthermore, growing funding and participation from the public and private sectors in R&D initiatives, as well as advancements in the infrastructure of the area, encourage market growth.


Chronic Kidney Disease Key Market Players & Competitive Insights


The chronic kidney disease market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Abbott (US), Siemens (Germany), Beckman Coulter (US), and F. Hoffmann-La Roche Ltd (Switzerland) the chronic kidney disease market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.


One of the primary business strategies adopted by manufacturers in the chronic kidney disease industry to benefit clients and expand the chronic kidney disease market sector is to manufacture locally to reduce operating costs.


GlaxoSmithKline Plc (UK) is a science-led healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines, and consumer healthcare. It is one of the few healthcare companies researching both medicines and vaccines for the world health organization’s three prime diseases, HIV/Aids, tuberculosis, meningococcal, and malaria. The company has also developed some of the leading medicines in these fields. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. For instance, in June 2020, GlaxoSmithKline Plc (UK) received regulatory approval for Duvroq (daprodustat) in Japan for patients with anemia due to chronic kidney disease.


Also, F. Hoffmann-La Roche Ltd (Roche) develops & markets products for diagnosis & treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company specializes in the field of molecular diagnostics & medicines for oncology, virology, inflammation, metabolism, central nervous system (CNS), clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. The firm operates in two major business segments, namely, pharmaceuticals and diagnostics. The company has strong presence in North America, Europe, Asia, and the Middle East.


Key Companies in the Chronic Kidney Disease Market include



  • Abbott (US)

  • Siemens (Germany)

  • Beckman Coulter (US)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • ACON Laboratories, Inc (US)

  • Nova Biomedical (US)

  • ARKRAY (Japan)

  • AstraZeneca (UK)

  • GlaxoSmithKline Plc (UK)

  • Bayer AG (Germany)


Chronic Kidney Disease Industry Developments


November 2023:Sun Pharma to co-market Zydus Lifesciences' drug for Chronic Kidney Disease (CKD)
Bayer launches pill to treat chronic kidney disease linked to diabetes

October 2023:Medtronic launches clinical trial to evaluate the safety and efficacy of its new renal denervation catheter for the treatment of CKD
AstraZeneca's Farxiga approved in the US for the treatment of CKD

September 2023:Fresenius Medical Care receives FDA breakthrough device designation for its latest hemodialysis machine
Boehringer Ingelheim and Eli Lilly announce new clinical trials for their oral SGLT2 inhibitor for CKD

August 2023:Novartis launches new global initiative to raise awareness of CKD and improve access to care
DaVita Kidney Care partners with Verily to develop new digital health tools for people with CKD

July 2023:Otsuka Pharmaceutical and Bristol Myers Squibb announce new clinical trials for their oral HIF-2α inhibitor for CKD AstraZeneca and Silence Therapeutics announce new clinical trials for their siRNA therapy for CKD


Chronic Kidney Disease Market Segmentation


Chronic Kidney Disease Diagnosis Outlook



  • Blood Test

  • Urine Test

  • Imaging Test

  • Kidney Biopsy


Chronic Kidney Disease Treatment Outlook



  • Drugs

  • Dialysis

  • Kidney Transplant


Chronic Kidney Disease Indication Outlook



Chronic Kidney Disease End User Outlook



  • Hospital & Clinics

  • Diagnostic Centers


Chronic Kidney Disease Regional Outlook



  • North America

  • US

  • Canada

  • Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Scope:

Report Attribute/Metric Details
Market Size 2022 USD 65.88 billion
Market Size 2023 USD 69.44 billion
Market Size 2030 USD 101.2 billion
Compound Annual Growth Rate (CAGR) 5.5% (2023-2030)
Base Year 2022
Forecast Period 2023-2030
Historical Data 2019 & 2021
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Diagnosis, Treatment, Indication, End User, And Region
Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Abbott (US), Siemens (Germany), Beckman Coulter (US), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc (US), Nova Biomedical (US), ARKRAY (Japan), AstraZeneca (UK), GlaxoSmithKline Plc (UK), and Bayer AG (Germany)
Key Market Opportunities New techniques for diagnosis of chronic kidney disease
Key Market Dynamics Increasing prevalence of kidney diseases Increasing number of biopsy procedures Rising demand for new techniques for diagnosis of chronic diseases.




Frequently Asked Questions (FAQ) :

The chronic kidney disease market is anticipated to reach USD 101.2 billion at a CAGR of 5.5% during the forecast period of 2023 to 2030.

The U.S. chronic kidney disease market is anticipated to reach USD 27.37-36.53 billion during the forecast period of 2023 to 2030.

The chronic kidney disease market is expected to register a CAGR of 5.5% during the forecast period of 2023 to 2030.

The North America chronic kidney disease market accounted for the largest share in the chronic kidney disease market.

Abbott (US), Siemens (Germany), Beckman Coulter (US), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc (US), Nova Biomedical (US), ARKRAY (Japan), AstraZeneca (UK), GlaxoSmithKline Plc (UK), and Bayer AG (Germany).

The Type 1 or Type 2 diabetes segment held the majority share in 2021 contributing to around 10.09% with respect to the chronic kidney disease market.

The hospital & clinics segment dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2023-2030.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid